Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin in the context of multiple sclerosis.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Thirteen patients with advanced multiple sclerosis and urge urinary incontinence were treated with desmopressin--a synthetic analogue of antidiuretic hormone--in a double-blind cross-over study.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Deamino Arginine Vasopressin, Multiple Sclerosis, Randomized Controlled Trials as Topic, Urinary Bladder, Neurogenic and Urinary Incontinence.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Vasopressin and Desmopressin in people with multiple sclerosis.

The publication is from 1990 (Scandinavian journal of urology and nephrology), a journal based in England.

More context: the Vasopressin compound page and the Desmopressin compound page, Multiple sclerosis research.